Sudo Biosciences Reports Positive Phase 1 Results for Brain-Penetrant TYK2 Inhibitor SUDO-550 in Neuroinflammatory Diseases
Key Insights
SUDO-550 demonstrated favorable safety and tolerability in Phase 1 trials with once-daily dosing and full central nervous system penetration.
The drug achieved exposure levels associated with greater than 90% inhibition of TYK2 (search)-mediated signaling in both the CNS and peripheral circulation.
Sudo Biosciences (search) plans to initiate a Phase 2 study in multiple sclerosis patients in the first half of 2026.
Sudo Biosciences (search) announced positive topline results from its Phase 1 first-in-human clinical trial of SUDO-550, an oral, CNS-penetrant, allosteric TYK2 (search) inhibitor designed for treating neuroinflammatory diseases. The study evaluated single and multiple ascending doses of SUDO-550 in healthy volunteers, including participants aged 65 and older.
Safety and Tolerability Profile
The Phase 1 results demonstrated that SUDO-550 was safe, well tolerated, and suitable for once-daily dosing across a wide dose range. Results in participants aged 65 and older were consistent with younger participants, supporting suitability for a broad patient population.
"SUDO-550 demonstrated low peak-to-trough variability following once daily dosing, reducing the risk of adverse effects that can be associated with peak drug concentrations, while providing continuous pharmacological activity over 24 hours," said Dr. Ian Mills, Chief Medical Officer at Sudo Biosciences (search).
Pharmacokinetic and Pharmacodynamic Properties
Pharmacokinetic analyses showed dose-proportional exposure, a long half-life, and equivalent free concentrations in plasma and cerebrospinal fluid (CSF), supporting convenient once-daily dosing. SUDO-550 achieved concentrations over 24-hours consistent with near complete (>90%) inhibition of TYK2 (search)-mediated pathways in the peripheral circulation and CNS, including activity in both microglia and astrocytes.
Pharmacodynamic assessments confirmed target engagement in both blood and CSF, demonstrating the drug's ability to effectively penetrate the blood-brain barrier and maintain therapeutic concentrations in the central nervous system.
Clinical Development Plans
Sudo Biosciences (search) plans to initiate a Phase 2 study of SUDO-550 in multiple sclerosis in the first half of 2026. The company is advancing a pipeline of highly selective, small molecule TYK2 (search) pseudokinase inhibitors designed to target the immune and inflammatory pathways that drive autoimmune and neurologic diseases.
"We believe SUDO-550 represents a new generation of selective TYK2 (search) inhibitors engineered to safely reach the brain and modulate the inflammatory processes driving some of the most challenging autoimmune and neurologic diseases," said Scott Byrd, Chief Executive Officer of Sudo Biosciences (search). "These results support advancing SUDO-550 into Phase 2 and brings us a step closer to changing the treatment landscape for patients who currently have limited options."
Mechanism of Action and Therapeutic Potential
SUDO-550 is positioned as a potential first-in-class and best-in-class, oral, CNS-penetrant allosteric TYK2 (search) inhibitor designed to achieve potent and selective inhibition of TYK2-mediated signaling across both the CNS and peripheral immune systems. By precisely modulating pathways driven by interleukin-12 (IL-12), interleukin-23 (IL-23), and Type I interferons, SUDO-550 has the potential to treat a broad range of autoimmune and neuroinflammatory diseases, including MS, ALS, and Alzheimer's disease.
Dr. Mills emphasized that "this unique clinical profile differentiates SUDO-550 from other TYK2 (search) inhibitors and highlights its potential to advance the standard of care for patients with MS and other neuroinflammatory diseases."